Download PDF
Z Gastroenterol 2021; 59(07): 691-776
DOI: 10.1055/a-1498-2512
Leitlinie

S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)

Markus Cornberg
1   Deutsches Zentrum für Infektionsforschung (DZIF), Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover; Centre for individualised infection Medicine (CiiM), Hannover
2   Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover
,
Lisa Sandmann
2   Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover
,
Ulrike Protzer
3   Institut für Virologie, Technische Universität München/Helmholtz Zentrum München, München
,
Claus Niederau
4   Oberhausen
,
Frank Tacke
5   Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité Universitätsmedizin Berlin, Berlin
,
Thomas Berg
6   Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig, Leipzig
,
Dieter Glebe
7   Institut für Medizinische Virologie, Nationales Referenzzentrum für Hepatitis-B-Viren und Hepatitis-D-Viren, Justus-Liebig-Universität Gießen, Gießen
,
Wolfgang Jilg
8   Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensberg, Regensburg
,
Heiner Wedemeyer
2   Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover
,
Stefan Wirth
9   Zentrum für Kinder- und Jugendmedizin, Helios Universitätsklinikum Wuppertal, Wuppertal
,
Christoph Höner zu Siederdissen
2   Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover
,
Petra Lynen-Jansen
10   Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Berlin
,
Pia van Leeuwen
10   Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Berlin
,
Jörg Petersen
11   IFI Institut für Interdisziplinäre Medizin an der Asklepios Klinik St. Georg, Hamburg
,
Collaborators:
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Besonderer Hinweis

Die Medizin unterliegt einem fortwährenden Entwicklungsprozess, sodass alle Angaben, insbesondere zu diagnostischen und therapeutischen Verfahren, immer nur dem Wissensstand zur Zeit der Drucklegung der Leitlinie entsprechen können. Hinsichtlich der angegebenen Empfehlungen zur Therapie und der Auswahl sowie Dosierung von Medikamenten wurde die größtmögliche Sorgfalt beachtet. Gleichwohl werden die Benutzer aufgefordert, die Beipackzettel und Fachinformationen der Hersteller zur Kontrolle heranzuziehen und im Zweifelsfall einen Spezialisten zu konsultieren. Fragliche Unstimmigkeiten sollen bitte im allgemeinen Interesse der Redaktion mitgeteilt werden. Der Benutzer selbst bleibt verantwortlich für jede diagnostische und therapeutische Applikation, Medikation und Dosierung.

In dieser Leitlinie sind eingetragene Warenzeichen (geschützte Warennamen) nicht besonders kenntlich gemacht. Es kann also aus dem Fehlen eines entsprechenden Hinweises nicht geschlossen werden, dass es sich um einen freien Warennamen handelt.

Das Werk ist in allen seinen Teilen urheberrechtlich geschützt. Jede Verwertung außerhalb der Bestimmungen des Urhebergesetzes ist ohne schriftliche Zustimmung der DGVS unzulässig und strafbar. Kein Teil des Werkes darf in irgendeiner Form ohne schriftliche Genehmigung reproduziert werden. Dies gilt insbesondere für Vervielfältigungen, Übersetzungen, Mikroverfilmungen und die Einspeicherung, Nutzung und Verwertung in elektronischen Systemen, Intranets und dem Internet.



Publication History

Article published online:
12 July 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 World Health Organization. Hepatitis B. 2019 Im Internet: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
    PubMedSearch in Google Scholar
  • 2 Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2018. 2019 Im Internet: https://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch_2018.pdf?__blob=publicationFile
    PubMedSearch in Google Scholar
  • 3 Stahmeyer JT, Becker H, Heidelberger S. et al Kosten einer leitliniengerechten Versorgung von Hepatitis-B-Patienten in Deutschland. Z Gastroenterol 2012; 50: 745-752
    PubMedSearch in Google Scholar
  • 4 Cornberg M, Protzer U, Dollinger MM. et al Prophylaxe, diagnostik und therapie der hepatitis-B-virus-(HBV-)infektion: „Upgrade“ der leitlinie, AWMF-register-Nr.: 021/011. Z Gastroenterol 2007; 45: 525-574
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Cornberg M, Protzer U, Petersen J. et al Prophylaxis, diagnosis and therapy of hepatitis B virus infection the German guideline. Z Gastroenterol 2011; 49: 871-930
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 European Association for the Study of the Liver (EASL). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398
    CrossrefPubMedSearch in Google Scholar
  • 7 Terrault NA, Bzowej NH, Chang KM. et al AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology 2016; 63: 261-283
    CrossrefPubMedSearch in Google Scholar
  • 8 Terrault NA, Lok ASF, McMahon BJ. et al Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560-1599
    CrossrefPubMedSearch in Google Scholar
  • 9 Greten TF, Malek NP, Schmidt S. et al Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2013; 51: 1269-1326
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Castera L, Yuen Chan HL, Arrese M. et al EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264
    CrossrefPubMedSearch in Google Scholar
  • 11 Sarrazin C, Zimmermann T, Berg T. et al Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2018; 56: 756
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Sarrazin C, Zimmermann T, Berg T. et al Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)- Infektion. Z Gastroenterol 2020; 58: 1110-1131
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Lynen Jansen P, Preiß JC, Muche-Borowski C. et al Das Leitlinienprogramm der DGVS. Z Gastroenterol 2013; 51: 643-650
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Muche-Borowski C, Selbmann H, Nothacker M. et al Das AWMF-Regelwerk Leitlinien. 2013
    PubMedSearch in Google Scholar
  • 15 Blümle A, Sow D, Nothacker M. et al Manual Systematische Recherche für Evidenzsynthesen und Leitlinien. Cochrane Deutschl Stift Inst für Evidenz der Medizin, Inst für Medizinische Biometrie und Stat Freiburg, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Inst für Medizinisches Wissensmanagement, Är 2019. 2. Auflage. 1-63
    PubMed
  • 16 Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 2006; 78: S66-S70
    CrossrefPubMedSearch in Google Scholar
  • 17 Westhoff TH, Jochimsen F, Schmittel A. et al Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930
    CrossrefPubMedSearch in Google Scholar
  • 18 Awerkiew S, Däumer M, Reiser M. et al Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38: 83-86
    CrossrefPubMedSearch in Google Scholar
  • 19 Brown RS, McMahon BJ, Lok ASF. et al Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology 2016; 63: 319-333
    CrossrefPubMedSearch in Google Scholar
  • 20 Li W, Jia L, Zhao X. et al Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: A meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol 2018; 18: 121
    CrossrefPubMedSearch in Google Scholar
  • 21 Hyun MH, Lee YS, Kim JH. et al Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther 2017; 45: 1493-1505
    CrossrefPubMedSearch in Google Scholar
  • 22 Pan CQ, Duan Z, Dai E. et al Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016; 374: 2324-2334
    CrossrefPubMedSearch in Google Scholar
  • 23 World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy. Geneva World Heal Organ; 2020 Licence: CC BY-NC-SA 3.0 IGO. Im Internet: https://apps.who.int/iris/bitstream/handle/10665/333391/9789240002708-eng.pdf?sequence=1&isAllowed=y
    PubMedSearch in Google Scholar
  • 24 Jourdain G, Ngo-Giang-Huong N, Harrison L. et al Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med 2018; 378: 911-923
    CrossrefPubMedSearch in Google Scholar
  • 25 Lin Y, Liu Y, Ding G. et al Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads. Sci Rep 8, 15514 (2018)
    PubMed
  • 26 Walz A, Wirth S, Hucke J. et al Vertical Transmission of Hepatitis B Virus (HBV) from Mothers Negative for HBV Surface Antigen and Positive for Antibody to HBV Core Antigen. J Infect Dis 2009; 200: 1227-1231
    CrossrefPubMedSearch in Google Scholar
  • 27 Robert Koch-Insitut. Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2009. Epidemiol Bull 2009; 20: 177-190
    PubMedSearch in Google Scholar
  • 28 Ganem D, Prince AM. Hepatitis B Virus Infection – Natural History and Clinical Consequences. N Engl J Med 2004; 350: 1118-1129
    CrossrefPubMedSearch in Google Scholar
  • 29 McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14: 381-396
    CrossrefPubMedSearch in Google Scholar
  • 30 Veldhuijzen IK, Toy M, Hahné SJM. et al Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective. Gastroenterology 2010; 138: 522-530
    CrossrefPubMedSearch in Google Scholar
  • 31 Colloredo Mels G, Bellati G, Leandro G. et al Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. Arch Virol Suppl 1993; 8: 203-211
    PubMedSearch in Google Scholar
  • 32 Chen CJ, Yang HI, Su J. et al Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level. J Am Med Assoc 2006; 295: 65-73
    CrossrefPubMedSearch in Google Scholar
  • 33 Iloeje UH, Yang HI, Su J. et al Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686
    CrossrefPubMedSearch in Google Scholar
  • 34 Chen G, Lin W, Shen F. et al Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-1803
    CrossrefPubMedSearch in Google Scholar
  • 35 Yang HI, Lu SN, Liaw YF. et al Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. N Engl J Med 2002; 347: 168-174
    CrossrefPubMedSearch in Google Scholar
  • 36 Cornberg M, Wong VWS, Locarnini S. et al The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017; 66: 398-411
    CrossrefPubMedSearch in Google Scholar
  • 37 Tseng TC, Liu CJ, Yang HC. et al Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013; 57: 441-450
    CrossrefPubMedSearch in Google Scholar
  • 38 Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40
    CrossrefPubMedSearch in Google Scholar
  • 39 Bremer B, Anastasiou OE, Ciesek S. et al Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. Antivir Ther 2019; 24: 117-123
    CrossrefPubMedSearch in Google Scholar
  • 40 Heese F, Görg C. Diagnostische wertigkeit einer internistischen referenzsonografie (DEGUM-Stufe 3). Ultraschall der Medizin 2006; 27: 220-224
    Thieme ConnectPubMedSearch in Google Scholar
  • 41 Sheu JC, Sung JL, Chen DS. et al Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259-266
    CrossrefPubMedSearch in Google Scholar
  • 42 Barbara L, Benzi G, Gaiani S. et al Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16: 132-137
    CrossrefPubMedSearch in Google Scholar
  • 43 Trinchet JC, Chaffaut C, Bourcier V. et al Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997
    CrossrefPubMedSearch in Google Scholar
  • 44 Wang JH, Chang KC, Kee KM. et al Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with chronic viral hepatitis: A randomized study in community. Am J Gastroenterol 2013; 108: 416-424
    CrossrefPubMedSearch in Google Scholar
  • 45 Sarri G, Westby M, Bermingham S. et al Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ 2013; 346: f3893
    CrossrefPubMedSearch in Google Scholar
  • 46 Singal A, Volk ML, Waljee A. et al Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47
    CrossrefPubMedSearch in Google Scholar
  • 47 Sarin SK, Kumar M, Lau GK. et al Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98
    CrossrefPubMedSearch in Google Scholar
  • 48 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016; 22: 18-75
    CrossrefPubMedSearch in Google Scholar
  • 49 Park JW, Lee JH, Suh KS. et al 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 2015; 16: 465-522
    CrossrefPubMedSearch in Google Scholar
  • 50 Thiele M, Gluud LL, Fialla AD. et al Large variations in risk of hepatocellular carcinoma and mortality in treatment Naïve hepatitis B patients: Systematic review with Metaanalyses. PLoS One 2014; 9: e107177
    CrossrefPubMedSearch in Google Scholar
  • 51 Galle PR, Forner A, Llovet JM. et al EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
    CrossrefPubMedSearch in Google Scholar
  • 52 Trevisani F, D’Intino PE, Morselli-Labate AM. et al Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575
    CrossrefPubMedSearch in Google Scholar
  • 53 Papatheodoridis G, Dalekos G, Sypsa V. et al PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-806
    CrossrefPubMedSearch in Google Scholar
  • 54 Wong GLH, Wong VWS, Choi PCL. et al Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010; 31: 1095-1103
    CrossrefPubMedSearch in Google Scholar
  • 55 Wong GLH, Chan HLY, Choi PCL. et al Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2014; 39: 197-208
    CrossrefPubMedSearch in Google Scholar
  • 56 Wong GLH, Wong VWS, Choi PCL. et al Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2009; 24: 1002-1007
    CrossrefPubMedSearch in Google Scholar
  • 57 Papatheodoridis GV, Manolakopoulos S, Liaw YF. et al Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review. J Hepatol 2012; 57: 196-202
    CrossrefPubMedSearch in Google Scholar
  • 58 Kumar M, Satapathy S, Monga R. et al A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101
    CrossrefPubMedSearch in Google Scholar
  • 59 Yu JW, Sun LJ, Zhao YH. et al The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55: 775-783
    CrossrefPubMedSearch in Google Scholar
  • 60 Wiegand J, Wedemeyer H, Franke A. et al Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: A prospective randomized double-blinded multicentre trial. J Viral Hepat 2014; 21: 744-750
    CrossrefPubMedSearch in Google Scholar
  • 61 Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E. et al Pharmacological interventions for acute hepatitis B infection: An attempted network meta-analysis. Cochrane Database Syst Rev 2017; 3: CD011645
    PubMedSearch in Google Scholar
  • 62 Tillmann HL, Hadem J, Leifeld L. et al Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-263
    CrossrefPubMedSearch in Google Scholar
  • 63 Jochum C, Maischack F, Anastasiou OE. et al Therapie der akuten fulminanten Hepatitis B mit Nucleos(t)id-Analogen ist sicher und führt nicht zur Chronifizierung der Hepatitis B. Z Gastroenterol 2016; 54: 1306-1311
    Thieme ConnectPubMedSearch in Google Scholar
  • 64 Yu JW, Sun LJ, Yan BZ. et al Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int 2011; 31: 499-506
    CrossrefPubMedSearch in Google Scholar
  • 65 Brunetto MR, Oliveri F, Coco B. et al Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: A long term cohort study. J Hepatol 2002; 36: 263-270
    CrossrefPubMedSearch in Google Scholar
  • 66 Kumar M, Sarin SK, Hissar S. et al Virologic and Histologic Features of Chronic Hepatitis B Virus-Infected Asymptomatic Patients With Persistently Normal ALT. Gastroenterology 2008; 134: 1376-1384
    CrossrefPubMedSearch in Google Scholar
  • 67 Lai M, Hyatt BJ, Nasser I. et al The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-767
    CrossrefPubMedSearch in Google Scholar
  • 68 Tsang PSY, Trinh H, Garcia RT. et al Significant Prevalence of Histologic Disease in Patients With Chronic Hepatitis B and Mildly Elevated Serum Alanine Aminotransferase Levels. Clin Gastroenterol Hepatol 2008; 6: 569-574
    CrossrefPubMedSearch in Google Scholar
  • 69 Papatheodoridis GV, Manesis EK, Manolakopoulos S. et al Is there a meaningful serum Hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?. Hepatology 2008; 48: 1451-1459
    CrossrefPubMedSearch in Google Scholar
  • 70 Wu IC, Lai CL, Bui Han SH. et al Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51: 1185-1189
    CrossrefPubMedSearch in Google Scholar
  • 71 Chen JD, Yang HI, Iloeje UH. et al Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death. Gastroenterology 2010; 138: 1747-1754
    CrossrefPubMedSearch in Google Scholar
  • 72 Kim JH, Sinn DH, Kang W. et al Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology 2017; 66: 335-343
    CrossrefPubMedSearch in Google Scholar
  • 73 Sinn DH, Lee J, Goo J. et al Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 2015; 62: 694-701
    CrossrefPubMedSearch in Google Scholar
  • 74 Zoutendijk R, Reijnders JG, Zoulim F. et al Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62: 760-765
    CrossrefPubMedSearch in Google Scholar
  • 75 Singal AK, Salameh H, Kuo YF. et al Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106
    CrossrefPubMedSearch in Google Scholar
  • 76 Lok ASF, McMahon BJ, Brown RS. et al Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 2016; 63: 284-306
    CrossrefPubMedSearch in Google Scholar
  • 77 Huang G, Li P, Lau WY. et al Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: A randomized controlled trial. Ann Surg 2018; 268: 943-954
    CrossrefPubMedSearch in Google Scholar
  • 78 Chen VL, Yeh ML, Le AK. et al Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Aliment Pharmacol Ther 2018; 48: 44-54
    CrossrefPubMedSearch in Google Scholar
  • 79 He L, Liu X, Zhao Y. et al Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Dis Markers 2017; 2017: 7075935
    PubMedSearch in Google Scholar
  • 80 Yuan P, Chen P, Qian Y. Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: An updated meta-analysis. Can J Gastroenterol Hepatol 2016; 2016: 5234969
    PubMedSearch in Google Scholar
  • 81 Xia BW, Zhang YC, Wang J. et al Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2015; 39: 458-468
    CrossrefPubMedSearch in Google Scholar
  • 82 Huang G, Lau WY, Wang ZG. et al Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma. Ann Surg 2015; 261: 56-66
    CrossrefPubMedSearch in Google Scholar
  • 83 Zhou Y, Zhang Z, Zhao Y. et al Antiviral therapy decreases recurrence of hepatitis b virus-related hepatocellular carcinoma after curative resection: A meta-analysis. World J Surg 2014; 38: 2395-2402
    CrossrefPubMedSearch in Google Scholar
  • 84 Yin J, Li N, Han Y. et al Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study. J Clin Oncol 2013; 31: 3647-3655
    CrossrefPubMedSearch in Google Scholar
  • 85 Wong JSW, Wong GLH, Tsoi KKF. et al Meta-analysis: The efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33: 1104-1112
    CrossrefPubMedSearch in Google Scholar
  • 86 Reddy KR, Beavers KL, Hammond SP. et al American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215-219
    CrossrefPubMedSearch in Google Scholar
  • 87 Sarmati L, Andreoni M, Antonelli G. et al Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation – a position paper. Clin Microbiol Infect 2017; 23: 935-940
    CrossrefPubMedSearch in Google Scholar
  • 88 Chen JZJQ, Liao ZW, Huang FL. et al Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Sci Rep 2017; 7: 4132
    CrossrefPubMedSearch in Google Scholar
  • 89 Glebe D, van Bömmel F, Dudareva S. et al Prävention der nosokomialen Übertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen Tätige: Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63: 218-225
    CrossrefPubMedSearch in Google Scholar
  • 90 Mazzaro C, Dal Maso L, Urraro T. et al Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie – GISC. Dig Liver Dis 2016; 48: 780-784
    CrossrefPubMedSearch in Google Scholar
  • 91 Wang WN, Wu MY, Ma FZ. et al Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis. Clin Nephrol 2016; 85: 21-29
    CrossrefPubMedSearch in Google Scholar
  • 92 Yang Y, Ma YP, Chen DP. et al A meta-Analysis of antiviral therapy for hepatitis b virus-Associated membranous nephropathy. PLoS One 2016; 11: e0160437
    CrossrefPubMedSearch in Google Scholar
  • 93 Hui CK, Leung N, Yuen ST. et al Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46: 395-401
    CrossrefPubMedSearch in Google Scholar
  • 94 Andreani T, Serfaty L, Mohand D. et al Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome. Clin Gastroenterol Hepatol 2007; 5: 636-641
    CrossrefPubMedSearch in Google Scholar
  • 95 Chu CM, Hung SJ, Lin J. et al Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-834
    CrossrefPubMedSearch in Google Scholar
  • 96 You SL, Yang HI, Chen CJ. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med 2004; 36: 215-224
    CrossrefPubMedSearch in Google Scholar
  • 97 Manno M, Cammà C, Schepis F. et al Natural history of chronic HBV carriers in Northern Italy: Morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-763
    CrossrefPubMedSearch in Google Scholar
  • 98 Tseng TC, Liu CJ, Yang HC. et al High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1149.e3
    CrossrefPubMedSearch in Google Scholar
  • 99 Tseng TC, Liu CJ, Chen CL. et al Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis 2013; 208: 584-593
    CrossrefPubMedSearch in Google Scholar
  • 100 Cornberg M, Suk-Fong Lok A, Terrault NA. et al Guidance for design and endpoints of clinical trials in chronic hepatitis B – Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. J Hepatol 2020; 72: 539-557
    CrossrefPubMedSearch in Google Scholar
  • 101 Kim GA, Lim YS, An J. et al HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis b: Clinical outcomes and durability. Gut 2014; 63: 1325-1332
    CrossrefPubMedSearch in Google Scholar
  • 102 Yuen MF, Wong DKH, Fung J. et al HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma. Gastroenterology 2008; 135: 1192-1199
    CrossrefPubMedSearch in Google Scholar
  • 103 Yip TCF, Wong GLH, Chan HLY. et al HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol 2019; 70: 361-370
    CrossrefPubMedSearch in Google Scholar
  • 104 Wong GLH, Chan HLY, Mak CWH. et al Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. Hepatology 2013; 58: 1537-1547
    CrossrefPubMedSearch in Google Scholar
  • 105 Arends P, Sonneveld MJ, Zoutendijk R. et al Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians. Gut 2015; 64: 1289-1295
    CrossrefPubMedSearch in Google Scholar
  • 106 Papatheodoridis GV, Lampertico P, Manolakopoulos S. et al Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J Hepatol 2010; 53: 348-356
    CrossrefPubMedSearch in Google Scholar
  • 107 Kim SS, Hwang JC, Lim SG. et al Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: Comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014; 109: 1223-1233
    CrossrefPubMedSearch in Google Scholar
  • 108 Marcellin P, Gane E, Buti M. et al Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013; 381: 468-475
    CrossrefPubMedSearch in Google Scholar
  • 109 Chang TT, Liaw YF, Wu SS. et al Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893
    CrossrefPubMedSearch in Google Scholar
  • 110 Niederau C, Heintges T, Lange S. et al Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427
    CrossrefPubMedSearch in Google Scholar
  • 111 Lin SM, Yu ML, Lee CM. et al Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52
    CrossrefPubMedSearch in Google Scholar
  • 112 Yuen MF, Hui CK, Cheng CC. et al Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-145
    CrossrefPubMedSearch in Google Scholar
  • 113 Jacobson IM, Washington MK, Buti M. et al Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clin Gastroenterol Hepatol 2017; 15: 1087-1094.e2
    CrossrefPubMedSearch in Google Scholar
  • 114 Liang KH, Hsu CW, Chang ML. et al Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. J Infect Dis 2016; 213: 966-974
    CrossrefPubMedSearch in Google Scholar
  • 115 Lau GKK, Piratvisuth T, Kang XL. et al Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695
    CrossrefPubMedSearch in Google Scholar
  • 116 Marcellin P, Lau GKK, Bonino F. et al Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
    CrossrefPubMedSearch in Google Scholar
  • 117 Sonneveld MJ, Zoutendijk R, Hansen BE. et al Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. Antivir Ther 2012; 17: 1605-1608
    CrossrefPubMedSearch in Google Scholar
  • 118 Van Nunen AB, Hansen BE, Suh DJ. et al Durability of HBeAG seroconversion following antiviral therapy for chronic hepatitis B: Relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424
    CrossrefPubMedSearch in Google Scholar
  • 119 Papatheodoridis GV, Chan HLY, Hansen BE. et al Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-967
    CrossrefPubMedSearch in Google Scholar
  • 120 Dave S, Park S, Murad MH. et al Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis. Hepatology 2021; 73: 68-78
    CrossrefPubMedSearch in Google Scholar
  • 121 Choi WM, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021; 19: 246-258.e9
    CrossrefPubMedSearch in Google Scholar
  • 122 Papatheodoridis GV, Dalekos GN, Idilman R. et al Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 2020; 73: 1037-1045
    CrossrefPubMedSearch in Google Scholar
  • 123 Voulgaris T, Papatheodoridi M, Lampertico P. et al Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int 2020; 40: 484-495
    CrossrefPubMedSearch in Google Scholar
  • 124 Liaw YF, Raptopoulou-Gigi M, Cheinquer H. et al Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology 2011; 54: 91-100
    CrossrefPubMedSearch in Google Scholar
  • 125 Shim JH, Lee HC, Kim KM. et al Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182
    CrossrefPubMedSearch in Google Scholar
  • 126 Chan HLY, Chen YC, Gane EJ. et al Randomized clinical trial: Efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-743
    CrossrefPubMedSearch in Google Scholar
  • 127 Liaw YF, Sung JJY, Chow WC. et al Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531
    CrossrefPubMedSearch in Google Scholar
  • 128 Papatheodoridis GV, Dimou E, Dimakopoulos K. et al Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-129
    CrossrefPubMedSearch in Google Scholar
  • 129 Zoulim F, Locarnini S. Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. Gastroenterology 2009; 137: 1593-608.e1–2
    CrossrefPubMedSearch in Google Scholar
  • 130 Warner N, Locarnini S. Mechanisms of hepatitis B virus resistance development. Intervirology 2014; 57: 218-224
    CrossrefPubMedSearch in Google Scholar
  • 131 Berg T, Zoulim F, Moeller B. et al Long-term efficacy and safety of emtricitabine plus tenofovir DF vsß. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 2014; 60: 715-722
    CrossrefPubMedSearch in Google Scholar
  • 132 Lim YS, Yoo BC, Byun KS. et al Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: Results of a randomised trial. Gut 2016; 65: 1042-1051
    CrossrefPubMedSearch in Google Scholar
  • 133 Tenney DJ, Rose RE, Baldick CJ. et al Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-911
    CrossrefPubMedSearch in Google Scholar
  • 134 Cathcart AL, Lik-Yuen Chan H, Bhardwaj N. et al No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis b infection. Antimicrob Agents Chemother 2018; 62: e01064-18
    CrossrefPubMedSearch in Google Scholar
  • 135 Agarwal K, Brunetto M, Seto WK. et al 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 2018; 68: 672-681
    CrossrefPubMedSearch in Google Scholar
  • 136 Buti M, Gane E, Seto WK. et al Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1: 196-206
    CrossrefPubMedSearch in Google Scholar
  • 137 Chan HLY, Fung S, Seto WK. et al Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1: 185-195
    CrossrefPubMedSearch in Google Scholar
  • 138 Lampertico P, Chan HLY, Janssen HLA. et al Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther 2016; 44: 16-34
    CrossrefPubMedSearch in Google Scholar
  • 139 Gane EJ, Deray G, Liaw YF. et al Telbivudine improves renal function in patients with chronic hepatitis b. Gastroenterology 2014; 146: 138-146.e5
    CrossrefPubMedSearch in Google Scholar
  • 140 Cholongitas E, Vasiliadis T, Goulis I. et al Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. J Viral Hepat 2015; 22: 574-580
    CrossrefPubMedSearch in Google Scholar
  • 141 Ha NB, Ha NB, Garcia RT. et al Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-734
    CrossrefPubMedSearch in Google Scholar
  • 142 Buti M, Fung S, Gane E. et al Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int 2015; 9: 243-250
    CrossrefPubMedSearch in Google Scholar
  • 143 Chang TT, Lai CL, Yoon SK. et al Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430
    CrossrefPubMedSearch in Google Scholar
  • 144 Tenney DJ, Rose RE, Baldick CJ. et al Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years-of therapy. Hepatology 2009; 49: 1503-1514
    CrossrefPubMedSearch in Google Scholar
  • 145 Hui AY, Chan HLY, Cheung AYK. et al Systematic review: Treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005; 22: 519-528
    CrossrefPubMedSearch in Google Scholar
  • 146 Liaw YF, Jia JD, Chan HLY. et al Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54: 1591-1599
    CrossrefPubMedSearch in Google Scholar
  • 147 Sonneveld MJ, Hansen BE, Piratvisuth T. et al Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 872-880
    CrossrefPubMedSearch in Google Scholar
  • 148 Chan HLY, Messinger D, Papatheodoridis GV. et al A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther 2018; 48: 547-555
    CrossrefPubMedSearch in Google Scholar
  • 149 Rijckborst V, Hansen BE, Ferenci P. et al Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-1011
    CrossrefPubMedSearch in Google Scholar
  • 150 Colombatto P, Oliveri F, Leandro G. et al Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis. Ital J Gastroenterol Hepatol 1997; 29: 441-447
    PubMedSearch in Google Scholar
  • 151 de Andrade LJO, D’Oliveira A, Silva CAC. et al A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis. Acta Gastroenterol Latinoam 2011; 41: 104-110
    PubMedSearch in Google Scholar
  • 152 ter Borg MJ, Hansen BE, Bigot G. et al ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol 2008; 42: 160-164
    CrossrefPubMedSearch in Google Scholar
  • 153 Wong GLH, Wong VWS, Chan HLY. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. J Viral Hepat 2014; 21: 825-834
    CrossrefPubMedSearch in Google Scholar
  • 154 Marcellin P, Ahn SH, Ma X. et al Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B. Gastroenterology 2016; 150: 134-144.e10
    CrossrefPubMedSearch in Google Scholar
  • 155 Qiu K, Liu B, Li SY. et al Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharmacol Ther 2018; 47: 1340-1348
    CrossrefPubMedSearch in Google Scholar
  • 156 Hongthanakorn C, Chotiyaputta W, Oberhelman K. et al Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53: 1854-1863
    CrossrefPubMedSearch in Google Scholar
  • 157 Yeo YH, Ho HJ, Yang HI. et al Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019; 156: 635-646.e9
    CrossrefPubMedSearch in Google Scholar
  • 158 Sheppard-Law S, Zablotska-Manos I, Kermeen M. et al Factors associated with HBV virological breakthrough. Antivir Ther 2017; 22: 53-60
    CrossrefPubMedSearch in Google Scholar
  • 159 van Vlerken LG, Arends P, Lieveld FI. et al Real life adherence of chronic hepatitis B patients to entecavir treatment. Dig Liver Dis 2015; 47: 577-583
    CrossrefPubMedSearch in Google Scholar
  • 160 Lim YS, Gwak GY, Choi J. et al Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. J Hepatol 2019; 71: 35-44
    CrossrefPubMedSearch in Google Scholar
  • 161 Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T. et al Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017; 67: 246-254
    CrossrefPubMedSearch in Google Scholar
  • 162 Park ES, Lee AR, Kim DH. et al Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 2019; 70: 1093-1102
    CrossrefPubMedSearch in Google Scholar
  • 163 Lin Y, Pan F, Wang Y. et al Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases. Oncol Lett 2017; 13: 307-314
    CrossrefPubMedSearch in Google Scholar
  • 164 Seto WK, Asahina Y, Brown TT. et al Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection. Clin Gastroenterol Hepatol 2018 Jun 20: S1542-3565(18)30633-5
    PubMed
  • 165 Fong TL, Lee BT, Tien A. et al Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepat 2019; 26: 561-567
    CrossrefPubMedSearch in Google Scholar
  • 166 Grossi G, Loglio A, Facchetti F. et al Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. J Hepatol 2018; 68: 195-198
    CrossrefPubMedSearch in Google Scholar
  • 167 Lim SG, Wai CT, Rajnakova A. et al Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51: 597-599
    CrossrefPubMedSearch in Google Scholar
  • 168 Papatheodoridis G, Vlachogiannakos I, Cholongitas E. et al Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016; 63: 1481-1492
    CrossrefPubMedSearch in Google Scholar
  • 169 Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: Cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2015; 42: 243-257
    CrossrefPubMedSearch in Google Scholar
  • 170 Raimondo G, Locarnini S, Pollicino T. et al Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 2019; 71: 397-408
    CrossrefPubMedSearch in Google Scholar
  • 171 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244.e3
    CrossrefPubMedSearch in Google Scholar
  • 172 Yip TCF, Wong GLH, Wong VWS. et al Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol 2018; 68: 63-72
    CrossrefPubMedSearch in Google Scholar
  • 173 Stelma F, van der Ree MH, Jansen L. et al HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up. J Viral Hepat 2017; 24: 1107-1113
    CrossrefPubMedSearch in Google Scholar
  • 174 Roushan MRH, Mohammadpour M, Baiany M. et al Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up. Epidemiol Infect 2016; 144: 2648-2653
    CrossrefPubMedSearch in Google Scholar
  • 175 Chaung KT, Ha NB, Trinh HN. et al High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012; 46: 865-870
    CrossrefPubMedSearch in Google Scholar
  • 176 Fung J, Lai CL, Tanaka Y. et al The duration of lamivudine therapy for chronic hepatitis b: Cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009; 104: 1940-1946
    CrossrefPubMedSearch in Google Scholar
  • 177 Qiu YW, Huang LH, Yang WL. et al Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis 2016; 43: 43-48
    CrossrefPubMedSearch in Google Scholar
  • 178 Chi H, Hansen BE, Yim C. et al Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther 2015; 41: 867-876
    CrossrefPubMedSearch in Google Scholar
  • 179 Chen YC, Peng CY, Jeng WJ. et al Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther 2015; 42: 1182-1191
    CrossrefPubMedSearch in Google Scholar
  • 180 Jung KS, Park JY, Chon YE. et al Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016; 51: 830-839
    CrossrefPubMedSearch in Google Scholar
  • 181 Berg T, Simon KG, Mauss S. et al Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study. J Hepatol 2017; 67: 918-924
    CrossrefPubMedSearch in Google Scholar
  • 182 Jeng WJ, Chen YC, Sheen IS. et al Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen–Negative Patients. Clin Gastroenterol Hepatol 2016; 14: 1813-1820.e1
    CrossrefPubMedSearch in Google Scholar
  • 183 Höner zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W. et al Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in Hepatitis B e antigen-negative patients. J Infect Dis 2018; 218: 1480-1484
    CrossrefPubMedSearch in Google Scholar
  • 184 Su TH, Yang HC, Tseng TC. et al Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy. J Infect Dis 2018; 217: 1193-1201
    CrossrefPubMedSearch in Google Scholar
  • 185 Kuo MTe, Hu TH, Hung CH. et al Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019; 49: 218-228
    CrossrefPubMedSearch in Google Scholar
  • 186 Höner Zu Siederdissen C, Rinker F, Maasoumy B. et al Viral and host responses after stopping long-term Nucleos(t)ide analogue therapy in HBeAg-negative chronic Hepatitis B. J Infect Dis 2016; 214: 1492-1497
    CrossrefPubMedSearch in Google Scholar
  • 187 Hadziyannis SJ, Sevastianos V, Rapti I. et al Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143: 629-636.e1
    CrossrefPubMedSearch in Google Scholar
  • 188 Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M. et al Daring-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther 2018; 23: 677-685
    CrossrefPubMedSearch in Google Scholar
  • 189 van Bömmel F, Stein K, Heyne R. et al Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial. J Hepatol 2020; 73: S118-S119
    CrossrefPubMedSearch in Google Scholar
  • 190 Zimmer CL, Rinker F, Höner Zu Siederdissen C. et al Increased NK Cell Function after Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated with Liver Damage and HBsAg Loss. Journal of Infectious Diseases. Oxford University Press; 2018: 1656-1666
    Search in Google Scholar
  • 191 Rinker F, Zimmer CL, Höner zu Siederdissen C. et al Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Hepatol 2018; 69: 584-593
    CrossrefPubMedSearch in Google Scholar
  • 192 Buster EHCJ, Hansen BE, Buti M. et al Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46: 388-394
    CrossrefPubMedSearch in Google Scholar
  • 193 Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T. et al Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. J Gastroenterol Hepatol 2016; 31: 1874-1881
    CrossrefPubMedSearch in Google Scholar
  • 194 Campistol JM, Esforzado N, Martínez J. et al Efficacy and tolerance of interferon-α2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-2709
    CrossrefPubMedSearch in Google Scholar
  • 195 Chan TM, Ho SKN, Tang CSO. et al Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology 2007; 12: 11-17
    CrossrefPubMedSearch in Google Scholar
  • 196 Coppolino G, Simeoni M, Summaria C. et al The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. J Nephrol 2015; 28: 393-402
    CrossrefPubMedSearch in Google Scholar
  • 197 Liu J, Wang J, Qi C. et al Baseline hepatitis B virus titer predicts initial postpartum hepatic flare. J Clin Gastroenterol 2018; 52: 902-907
    CrossrefPubMedSearch in Google Scholar
  • 198 Shang J, Wen Q, Wang CC. et al Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. J Viral Hepat 2017; 24: 43-48
    CrossrefPubMedSearch in Google Scholar
  • 199 Antiretroviral Pregnancy Registry Interim Report for 1 January 1989–31 January 2020*. http://www.apregistry.com. 2020
    PubMedSearch in Google Scholar
  • 200 Yang M, Qin Q, Fang Q. et al Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: A meta-analysis. BMC Pregnancy Childbirth 2017; 17: 303
    CrossrefPubMedSearch in Google Scholar
  • 201 Chen HL, Cai JY, Song YP. et al Vaginal delivery and HBV mother to child transmission risk after immunoprophylaxis: A systematic review and a meta-analysis. Midwifery 2019; 74: 116-125
    CrossrefPubMedSearch in Google Scholar
  • 202 Pan CQ, Zou HB, Chen Y. et al Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis b surface antigen-positive women to their infants. Clin Gastroenterol Hepatol 2013; 11: 1349-1355
    CrossrefPubMedSearch in Google Scholar
  • 203 Wang M, Bian Q, Zhu Y. et al Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther 2019; 49: 211-217
    CrossrefPubMedSearch in Google Scholar
  • 204 Hou J, Wang G, Wang F. et al Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017; 5: 297-318
    CrossrefPubMedSearch in Google Scholar
  • 205 Hou J, Cui F, Ding Y. et al Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clin Gastroenterol Hepatol 2019; 17: 1929-1936.e1
    CrossrefPubMedSearch in Google Scholar
  • 206 Ehrhardt S, Xie C, Guo N. et al Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence. Clin Infect Dis 2015; 60: 275-278
    CrossrefPubMedSearch in Google Scholar
  • 207 Hu X, Wang L, Xu F. Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage. Int J Infect Dis 2019; 87: 8-12
    CrossrefPubMedSearch in Google Scholar
  • 208 Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. Aids 2017; 31: 213-232
    CrossrefPubMedSearch in Google Scholar
  • 209 Mugwanya KK, John-Stewart G, Baeten J. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Expert Opin Drug Saf 2017; 16: 867-871
    CrossrefPubMedSearch in Google Scholar
  • 210 Shi Z, Yang Y, Wang H. et al Breastfeeding of newborns by mothers carrying hepatitis B virus: A meta-analysis and systematic review. Arch Pediatr Adolesc Med 2011; 165: 837-846
    CrossrefPubMedSearch in Google Scholar
  • 211 Paul S, Dickstein A, Saxena A. et al Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology 2017; 66: 379-388
    CrossrefPubMedSearch in Google Scholar
  • 212 Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F. et al Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy. Medicine (Baltimore) 2011; 90: 359-371
    CrossrefPubMedSearch in Google Scholar
  • 213 Voican CS, Mir O, Loulergue P. et al Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 2016; 27: 2172-2184
    CrossrefPubMedSearch in Google Scholar
  • 214 Mallet V, van Bömmel F, Doerig C. et al Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: Recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 2016; 16: 606-617
    CrossrefPubMedSearch in Google Scholar
  • 215 Barone M, Notarnicola A, Lopalco G. et al Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection. Hepatology 2015; 62: 40-46
    CrossrefPubMedSearch in Google Scholar
  • 216 Caocci G, Murgia F, Podda L. et al Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28: 225-227
    CrossrefPubMedSearch in Google Scholar
  • 217 Kirito K, Sakamoto M, Enomoto N. Elevation of the hepatitis b virus dna during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med 2016; 55: 1341-1344
    CrossrefPubMedSearch in Google Scholar
  • 218 Godbert B, Petitpain N, Lopez A. et al Hepatitis B reactivation and immune check point inhibitors. Dig Liver Dis 2021; 53: 452-455
    CrossrefPubMedSearch in Google Scholar
  • 219 Lee PC, Chao Y, Chen MH. et al Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020; 8: 1072
    PubMedSearch in Google Scholar
  • 220 Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?. Clin Liver Dis 2020; 24: 317-333
    CrossrefPubMedSearch in Google Scholar
  • 221 Gane E, Verdon DJ, Brooks AE. et al Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol 2019; 71: 900-907
    CrossrefPubMedSearch in Google Scholar
  • 222 Jang JW, Kim YW, Lee SW. et al Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS One 2015; 10: e0122041
    CrossrefPubMedSearch in Google Scholar
  • 223 Lao XM, Luo G, Ye LT. et al Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int 2013; 33: 595-604
    CrossrefPubMedSearch in Google Scholar
  • 224 Huang S, Xia Y, Lei Z. et al Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma. J Am Coll Surg 2017; 224: 283-293.e4
    CrossrefPubMedSearch in Google Scholar
  • 225 Yoo SH, Jang JW, Kwon JH. et al Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. Clin Mol Hepatol 2016; 22: 458-465
    CrossrefPubMedSearch in Google Scholar
  • 226 Huang H, Li X, Zhu J. et al Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: A randomized clinical trial. JAMA – J Am Med Assoc 2014; 312: 2521-2530
    CrossrefPubMedSearch in Google Scholar
  • 227 Zhang MY, Zhu GQ, Shi KQ. et al Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget 2016; 7: 30642-30658
    CrossrefPubMedSearch in Google Scholar
  • 228 Grossi G, Viganò M, Facchetti F. et al Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: Two case reports. Haematologica 2017; 102: e423-e426
    CrossrefPubMedSearch in Google Scholar
  • 229 Buti M, Manzano ML, Morillas RM. et al Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017; 12: e0184550
    CrossrefPubMedSearch in Google Scholar
  • 230 Nakaya A, Fujita S, Satake A. et al Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?. Leuk Res 2016; 50: 46-49
    CrossrefPubMedSearch in Google Scholar
  • 231 Liaw YF, Sheen IS, Lee CM. et al Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72
    CrossrefPubMedSearch in Google Scholar
  • 232 Jang JW, Choi JY, Kim YS. et al Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015; 61: 1809-1820
    CrossrefPubMedSearch in Google Scholar
  • 233 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. J Hepatol 2012; 57: 442-450
    CrossrefPubMedSearch in Google Scholar
  • 234 Burra P, Germani G, Adam R. et al Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. J Hepatol 2013; 58: 287-296
    CrossrefPubMedSearch in Google Scholar
  • 235 De Simone P, Romagnoli R, Tandoi F. et al Early introduction of subcutaneous hepatitis B immunoglobulin following liver transplantation for hepatitis B virus infection: A prospective, multicenter study. Transplantation 2016; 100: 1507-1512
    CrossrefPubMedSearch in Google Scholar
  • 236 Zheng JN, Zou TT, Zou H. et al Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. Expert Rev Anti Infect Ther 2016; 14: 979-987
    CrossrefPubMedSearch in Google Scholar
  • 237 Fernández I, Loinaz C, Hernández O. et al Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Transpl Infect Dis 2015; 17: 695-701
    CrossrefPubMedSearch in Google Scholar
  • 238 Choudhary NS, Saraf N, Saigal S. et al Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: The ideal post-transplant hepatitis B virus prophylaxis?. Transpl Infect Dis 2015; 17: 329-333
    CrossrefPubMedSearch in Google Scholar
  • 239 Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis b virus recurrence after liver transplantation: A systematic review. Am J Transplant 2013; 13: 353-362
    CrossrefPubMedSearch in Google Scholar
  • 240 Manini MA, Whitehouse G, Bruce M. et al Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis 2018; 50: 944-953
    CrossrefPubMedSearch in Google Scholar
  • 241 Sripongpun P, Mannalithara A, Kwo PY. et al Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. Clin Gastroenterol Hepatol 2020; 18: 747-749
    CrossrefPubMedSearch in Google Scholar
  • 242 Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010; 55: 505-509
    CrossrefPubMedSearch in Google Scholar
  • 243 Wong SN, Chu CJ, Wai CT. et al Low risk of hepatitits B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transplant 2007; 13: 374-381
    CrossrefPubMedSearch in Google Scholar
  • 244 Fung J, Chan SC, Cheung C. et al Oral nucleoside/nucleotide analogs without hepatitis b immune globulin after liver transplantation for hepatitis b. Am J Gastroenterol 2013; 108: 942-948
    CrossrefPubMedSearch in Google Scholar
  • 245 Terrault N. Editorial: Prophylaxis in hbv-infected liver transplant patients: End of the HBIG era?. Am J Gastroenterol 2013; 108: 949-951
    CrossrefPubMedSearch in Google Scholar
  • 246 Wang P, Tam N, Wang H. et al Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One 2014; 9: e104480
    CrossrefPubMedSearch in Google Scholar
  • 247 Lens S, García-Eliz M, Fernández I. et al Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. Liver Int 2018; 38: 1940-1950
    CrossrefPubMedSearch in Google Scholar
  • 248 Idilman R, Akyildiz M, Keskin O. et al The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence. Clin Transplant 2016; 30: 1216-1221
    CrossrefPubMedSearch in Google Scholar
  • 249 Cholongitas E, Goulis I, Antoniadis N. et al Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation. Transpl Infect Dis 2016; 18: 667-673
    CrossrefPubMedSearch in Google Scholar
  • 250 Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol 2011; 55: 507-509
    CrossrefPubMedSearch in Google Scholar
  • 251 Karlas T, Hartmann J, Weimann A. et al Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis 2011; 13: 299-302
    CrossrefPubMedSearch in Google Scholar
  • 252 Roche B, Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis 2012; 32: 245-255
    Thieme ConnectPubMedSearch in Google Scholar
  • 253 Kasraianfard A, Watt KD, Lindberg L. et al HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Int Rev Immunol 2016; 35: 312-324
    PubMedSearch in Google Scholar
  • 254 Radhakrishnan K, Chi A, Quan DJ. et al Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients. Transplantation 2017; 101: 2079-2082
    CrossrefPubMedSearch in Google Scholar
  • 255 Teperman LW, Poordad F, Bzowej N. et al Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transplant 2013; 19: 594-601
    CrossrefPubMedSearch in Google Scholar
  • 256 Stärkel P, Stoffel M, Lerut J. et al Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transplant 2005; 11: 1228-1234
    CrossrefPubMedSearch in Google Scholar
  • 257 Sanchez-Fueyo A, Rimola A, Grande L. et al Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501
    CrossrefPubMedSearch in Google Scholar
  • 258 Rosenau J, Hooman N, Rifai K. et al Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: Failure of humoral and cellular immune response. Transpl Int 2006; 19: 828-833
    CrossrefPubMedSearch in Google Scholar
  • 259 Margreiter R, Kramar R, Huber C. et al Combined Liver and Kidney Transplantation. Lancet 1984; 323: 1077-1078
    CrossrefPubMedSearch in Google Scholar
  • 260 Ruiz R, Kunitake H, Wilkinson AH. et al Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141: 735-741
    CrossrefPubMedSearch in Google Scholar
  • 261 Kirchner GI, Rifai K, Cantz T. et al Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transplant 2006; 12: 1268-1277
    CrossrefPubMedSearch in Google Scholar
  • 262 Jalanko H, Pakarinen M. Combined liver and kidney transplantation in children. Pediatr Nephrol 2014; 29: 805-814
    CrossrefPubMedSearch in Google Scholar
  • 263 Pöge U, Gerhardt T, Palmedo H. et al MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5: 1306-1311
    CrossrefPubMedSearch in Google Scholar
  • 264 Neumann UP, Lang M, Moloenhauer A. et al Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001; 71: 1163-1168
    CrossrefPubMedSearch in Google Scholar
  • 265 Olausson M, Mjörnstedt L, Nordén G. et al Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7: 130-136
    CrossrefPubMedSearch in Google Scholar
  • 266 Hwang JP, Lok ASF. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 209-219
    CrossrefPubMedSearch in Google Scholar
  • 267 Kanaan N, Kabamba B, Maréchal C. et al Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. J Clin Virol 2012; 55: 233-238
    CrossrefPubMedSearch in Google Scholar
  • 268 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 2017; 152: 1297-1309
    CrossrefPubMedSearch in Google Scholar
  • 269 Shang J, Wang H, Sun J. et al A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: A single-institutional experience. Bone Marrow Transplant 2016; 51: 581-586
    CrossrefPubMedSearch in Google Scholar
  • 270 Seto WK, Chan TSY, Hwang YY. et al Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology 2017; 65: 1451-1461
    CrossrefPubMedSearch in Google Scholar
  • 271 O’Grady J. The immunoreactive patient: Rejection and autoimmune disease. Liver Transplant 2011; 17 (Suppl. 03) S29-S33
    CrossrefPubMedSearch in Google Scholar
  • 272 Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts – a systematic analysis. Clin Transplant 2011; 25: E243-E249
    CrossrefPubMedSearch in Google Scholar
  • 273 Huprikar S, Danziger-Isakov L, Ahn J. et al Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management. Am J Transplant 2015; 15: 1162-1172
    CrossrefPubMedSearch in Google Scholar
  • 274 Wright AJ, Fishman JA, Chung RT. Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: A cost-effectiveness analysis. Am J Transplant 2014; 14: 629-634
    CrossrefPubMedSearch in Google Scholar
  • 275 Chang MS, Olsen SK, Pichardo EM. et al Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: A 12-year experience. Transplantation 2013; 95: 960-965
    CrossrefPubMedSearch in Google Scholar
  • 276 Chotiyaputta W, Pelletier SJ, Fontana RJ. et al Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int 2010; 4: 707-715
    CrossrefPubMedSearch in Google Scholar
  • 277 Leong J, Coty P, Isabel Fiel M. et al Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts. Hepatol Res 2014; 44: 1248-1252
    CrossrefPubMedSearch in Google Scholar
  • 278 Yamashiki N, Yoshizawa A, Ueda Y. et al The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of anti-HBc–positive livers. Pediatr Transplant 2018; 22: e13227
    CrossrefPubMedSearch in Google Scholar
  • 279 Yang A, Guo Z, Ren Q. et al Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study. PLoS One 2017; 12: e0188190
    CrossrefPubMedSearch in Google Scholar
  • 280 Wang SH, Loh PY, Lin TL. et al Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen–positive graft. Liver Transplant 2017; 23: 1266-1272
    CrossrefPubMedSearch in Google Scholar
  • 281 Yoshizawa A, Yamashiki N, Ueda Y. et al Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatol Res 2016; 46: 541-551
    CrossrefPubMedSearch in Google Scholar
  • 282 Verna EC. Vaccination to prevent de novo hepatitis B: Are there patients who do not need antiviral prophylaxis?. Liver Transplant 2017; 23: 1253-1254
    CrossrefPubMedSearch in Google Scholar
  • 283 Mahboobi N, Tabatabaei SV, Blum HE. et al Renal grafts from anti-hepatitis B core-positive donors: A quantitative review of the literature. Transpl Infect Dis 2012; 14: 445-451
    CrossrefPubMedSearch in Google Scholar
  • 284 Manickam P, Krishnamoorthi R, Kanaan Z. et al Prognostic implications of recipient or donor hepatitis B seropositivity in thoracic transplantation: Analysis of 426 hepatitis B surface antigen-positive recipients. Transpl Infect Dis 2014; 16: 597-604
    CrossrefPubMedSearch in Google Scholar
  • 285 Satterthwaite R, Ozgu I, Shidban H. et al Risks of transplanting kidneys from hepatitis B surface antigen- negative, hepatitis B core antibody-positive donors. Transplantation 1997; 64: 432-435
    CrossrefPubMedSearch in Google Scholar
  • 286 Yu S, Yu J, Zhang W. et al Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation. J Hepatol 2014; 61: 809-815
    CrossrefPubMedSearch in Google Scholar
  • 287 Saidi RF, Jabbour N, Shah SA. et al Liver transplantation from hepatitis B surface antigen-positive donors. Transplant Proc 2013; 45: 279-280
    CrossrefPubMedSearch in Google Scholar
  • 288 Chancharoenthana W, Townamchai N, Pongpirul K. et al The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: A retrospective, propensity score-matched study. Am J Transplant 2014; 14: 2814-2820
    CrossrefPubMedSearch in Google Scholar
  • 289 Jiang H, Wu J, Zhang X. et al Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: A prospective nonrandomized controlled study from a single center. Am J Transplant 2009; 9: 1853-1858
    CrossrefPubMedSearch in Google Scholar
  • 290 Magiorkinis E, Paraskevis D, Pavlopoulou ID. et al Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative recipients: A case of post-transplant fulminant hepatitis associated with an extensively mutated hepatitis B virus strain and review of the current literature. Transpl Infect Dis 2013; 15: 393-399
    CrossrefPubMedSearch in Google Scholar
  • 291 Giaccone L, Festuccia M, Marengo A. et al Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010; 16: 809-817
    CrossrefPubMedSearch in Google Scholar
  • 292 Lau GKK, Lie AKW, Kwong YL. et al A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000; 96: 452-458
    CrossrefPubMedSearch in Google Scholar
  • 293 Hui CK, Lie A, Au WY. et al Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant 2005; 5: 1437-1445
    CrossrefPubMedSearch in Google Scholar
  • 294 Franchello A, Ghisetti V, Marzano A. et al Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transplant 2005; 11: 922-928
    CrossrefPubMedSearch in Google Scholar
  • 295 Su WJ, Ho MC, Ni YH. et al High-titer antibody to hepatitis b surface antigen before liver transplantation can prevent de novo hepatitis b infection. J Pediatr Gastroenterol Nutr 2009; 48: 203-208
    CrossrefPubMedSearch in Google Scholar
  • 296 Kim KH, Sang HA, Hyo YC. et al Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol 2004; 19: 847-853
    CrossrefPubMedSearch in Google Scholar
  • 297 Gutierrez Domingo I, Pascasio Acevedo JM, Alcalde Vargas A. et al Response to vaccination against hepatitis B virus with a schedule of four 40-μg doses in cirrhotic patients evaluated for liver transplantation: Factors associated with a response. In: Transplantation Proceedings 2012: 1499-1501
    PubMedSearch in Google Scholar
  • 298 Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO). Epidemiol Bull 2020; 34. Im Internet: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2020/Ausgaben/34_20.pdf?__blob=publicationFile
    PubMed
  • 299 Hilgendorf I, Freund M, Jilg W. et al Vaccination of allogeneic haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHD. Vaccine 2011; 29: 2825-2833
    CrossrefPubMedSearch in Google Scholar
  • 300 Kim DK, Riley LE, Harriman KH. et al Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older – United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66: 136-138
    CrossrefPubMedSearch in Google Scholar
  • 301 Sawyer MH, Hoerger TJ, Murphy TV. et al Use of hepatitis B vaccination for adults with diabetes mellitus: Recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 2011; 60: 1709-1711
    PubMedSearch in Google Scholar
  • 302 World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Glob Hepat Program Dep HIV/AIDS; 2016: 56
    PubMedSearch in Google Scholar
  • 303 Poethko-Müller C, Zimmermann R, Hamouda O. et al Die Seroepidemiologie der Hepatitis A, B und C in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz 2013; 56: 707-715
    CrossrefPubMedSearch in Google Scholar
  • 304 Heidrich B, Cetindere A, Beyaz M. et al High prevalence of hepatitis markers in immigrant populations: A prospective screening approach in a real-world setting. Eur J Gastroenterol Hepatol 2014; 26: 1090-1097
    CrossrefPubMedSearch in Google Scholar
  • 305 Centers for Disease Control and Prevention. Immunization of Health-Care Personnel Recommendations of the Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report. Mmwr 2011; 60: 1-46 . Im Internet: http://www.cdc.gov/mmwr/cme/conted.html
    PubMedSearch in Google Scholar
  • 306 Huzly D, Schenk T, Jilg W. et al Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 2008; 46: 1298-1306
    CrossrefPubMedSearch in Google Scholar
  • 307 Brunskole Hummel I, Huber B, Wenzel JJ. et al Markers of protection in children and adolescents six to fourteen years after primary hepatitis B vaccination in real life: A pilot study. Pediatr Infect Dis J 2016; 35: 286-291
    CrossrefPubMedSearch in Google Scholar
  • 308 Schönberger K, Riedel C, Rückinger S. et al Determinants of long-term protection after hepatitis b vaccination in infancy: A meta-analysis. Pediatr Infect Dis J 2013; 32: 307-313
    CrossrefPubMedSearch in Google Scholar
  • 309 Chiara F, Bartolucci GB, Mongillo M. et al Hepatitis B vaccination at three months of age: A successful strategy?. Vaccine 2013; 31: 1696-1700
    CrossrefPubMedSearch in Google Scholar
  • 310 Middleman AB, Baker CJ, Kozinetz CA. et al Duration of protection after infant hepatitis B vaccination series. Pediatrics 2014; 133: e1500-e1507
    CrossrefPubMedSearch in Google Scholar
  • 311 Dini G, Toletone A, Barberis I. et al Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy. Hum Vaccines Immunother 2017; 13: 440-444
    CrossrefPubMedSearch in Google Scholar
  • 312 Bruce MG, Bruden D, Hurlburt D. et al Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis 2016; 214: 16-22
    CrossrefPubMedSearch in Google Scholar
  • 313 Harder T, Remschmidt C, Falkenhorst G. et al Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany. Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz 2013; 56: 1565-1576
    CrossrefPubMedSearch in Google Scholar
  • 314 FitzSimons D, Hendrickx G, Vorsters A. et al Hepatitis B vaccination: A completed schedule enough to control HBV lifelong?. Milan, Italy, 17–18 November 2011. Vaccine 2013; 31: 584-590
    CrossrefPubMedSearch in Google Scholar
  • 315 World Health Organization. Weekly epidemiological record. Wkly Epidemiol Rec 2009; 84, 40: 405-420
    PubMedSearch in Google Scholar
  • 316 Werner JM, Abdalla A, Gara N. et al The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013; 145: 1026-1034
    CrossrefPubMedSearch in Google Scholar
  • 317 David MC, Ha SH, Paynter S. et al A systematic review and meta-analysis of management options for adults who respond poorly to hepatitis B vaccination. Vaccine 2015; 33: 6564-6569
    CrossrefPubMedSearch in Google Scholar
  • 318 Robert Koch-Institut. Epidemiologisches Bulletin. Epidemiol Bull 2013; 36/37: 371-381 . Im Internet: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/36_37_13.pdf?__blob=publicationFile
    PubMedSearch in Google Scholar
  • 319 Stramer SL, Wend U, Candotti D. et al Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364: 236-247
    CrossrefPubMedSearch in Google Scholar
  • 320 Launay O, Rosenberg AR, Rey D. et al Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1 Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med 2016; 176: 603-610
    CrossrefPubMedSearch in Google Scholar
  • 321 Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 2017; 34: 333-376
    PubMedSearch in Google Scholar
  • 322 Mouchet J, Salvo F, Raschi E. et al Hepatitis B vaccination and the putative risk of central demyelinating diseases – A systematic review and meta-analysis. Vaccine 2018; 36: 1548-1555
    CrossrefPubMedSearch in Google Scholar
  • 323 Vogel G. Europe’s top court alarms vaccine experts. Science (80-) 2017; 356: 1320
    CrossrefPubMedSearch in Google Scholar
  • 324 Mertens T. GfV-Stellungnahme zum EU-Urteil HBV-Impfung-MS-3-2017-06-23. Online 2017; Im Internet: https://www.g-f-v.org/node/716
    PubMed
  • 325 Sheffield JS, Hickman A, Tang J. et al Efficacy of an accelerated hepatitis b vaccination program during pregnancy. Obstet Gynecol 2011; 117: 1130-1135
    CrossrefPubMedSearch in Google Scholar
  • 326 Raven SFH, De Heus B, Wong A. et al Fluctuation of Viremia in Hepatitis B Virus-Infected Healthcare Workers Performing Exposure-Prone Procedures in the Netherlands. Infect Control Hosp Epidemiol 2016; 37: 655-660
    CrossrefPubMedSearch in Google Scholar
  • 327 Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol 2015; 204: 39-55
    CrossrefPubMedSearch in Google Scholar
  • 328 Fattovich G, Boscaro S, Noventa F. et al Influence of Hepatitis Delta Virus Infection on Progression to Cirrhosis in Chronic Hepatitis Type B. J Infect Dis 1987; 155: 931-935
    CrossrefPubMedSearch in Google Scholar
  • 329 Fattovich G, Giustina G, Christensen E. et al Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000; 46: 420-426
    CrossrefPubMedSearch in Google Scholar
  • 330 Miao Z, Zhang S, Ou X. et al Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis 2020; 221: 1677-1687
    CrossrefPubMedSearch in Google Scholar
  • 331 Stockdale AJ, Kreuels B, Henrion MYR. et al The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol 2020; 73: 523-532
    CrossrefPubMedSearch in Google Scholar
  • 332 Alfaiate D, Clément S, Gomes D. et al Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol 2020; 73: 533-539
    CrossrefPubMedSearch in Google Scholar
  • 333 Le Gal F, Brichler S, Drugan T. et al Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. Hepatology 2017; 66: 1826-1841
    CrossrefPubMedSearch in Google Scholar
  • 334 Su CW, Huang YH, Huo TI. et al Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients. Gastroenterology 2006; 130: 1625-1635
    CrossrefPubMedSearch in Google Scholar
  • 335 Spaan M, Carey I, Bruce M. et al Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. J Hepatol 2020; 72: 1097-1104
    CrossrefPubMedSearch in Google Scholar
  • 336 Roulot D, Brichler S, Layese R. et al Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J Hepatol 2020; 73: 1046-1062
    CrossrefPubMedSearch in Google Scholar
  • 337 Wranke A, Wedemeyer H. Antiviral therapy of hepatitis delta virus infection – progress and challenges towards cure. Curr Opin Virol 2016; 20: 112-118
    CrossrefPubMedSearch in Google Scholar
  • 338 Wedemeyer H, Yurdaydìn C, Dalekos GN. et al Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331
    CrossrefPubMedSearch in Google Scholar
  • 339 Wedemeyer H, Yurdaydin C, Hardtke S. et al PEG-Interferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis 2019; 19: 275-286
    CrossrefPubMedSearch in Google Scholar
  • 340 Heidrich B, Yurdaydin C, Kabaçam G. et al Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014; 60: 87-97
    CrossrefPubMedSearch in Google Scholar
  • 341 Yurdaydin C, Keskin O, Kalkan Ç. et al Interferon Treatment Duration in Patients with Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. Journal of Infectious Diseases 2018; 217: 1184-1192
    CrossrefPubMedSearch in Google Scholar
  • 342 Wranke A, Serrano BC, Heidrich B. et al Antiviral treatment and liver-related complications in hepatitis delta. Hepatology 2017; 65: 414-425
    CrossrefPubMedSearch in Google Scholar
  • 343 Kamal H, Westman G, Falconer K. et al Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology 2020; 72: 1177-1190
    CrossrefPubMedSearch in Google Scholar
  • 344 Niro GA, Smedile A, Fontana R. et al HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. Aliment Pharmacol Ther 2016; 44: 620-628
    CrossrefPubMedSearch in Google Scholar
  • 345 Yurdaydin C, Abbas Z, Buti M. et al Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol 2019; 70: 1008-1015
    CrossrefPubMedSearch in Google Scholar
  • 346 Loglio A, Ferenci P, Uceda Renteria SC. et al Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients. J Hepatol 2019; 71: 834-839
    CrossrefPubMedSearch in Google Scholar
  • 347 Keskin O, Wedemeyer H, Tüzün A. et al Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Clin Gastroenterol Hepatol 2015; 13: 2342-2349.e2
    CrossrefPubMedSearch in Google Scholar
  • 348 Heller T, Rotman Y, Koh C. et al Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 2014; 40: 93-104
    CrossrefPubMedSearch in Google Scholar
  • 349 Yurdaydin C, Bozkaya H, Gürel S. et al Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37: 266-271
    CrossrefPubMedSearch in Google Scholar
  • 350 Niro GA, Ciancio A, Tillman HL. et al Lamivudine therapy in chronic delta hepatitis: A multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22: 227-232
    CrossrefPubMedSearch in Google Scholar
  • 351 Kabaçam G, Önder FO, Yakut M. et al Entecavir treatment of chronic hepatitis D. Clin Infect Dis 2012; 55: 645-650
    CrossrefPubMedSearch in Google Scholar
  • 352 Soriano V, Vispo E, Sierra-Enguita R. et al Efficacy of prolonged tenofovir therapy on Hepatitis delta in HIV-infected patients. Aids 2014; 28: 2389-2394
    CrossrefPubMedSearch in Google Scholar
  • 353 Béguelin C, Friolet N, Moradpour D. et al Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clin Infect Dis 2017; 64: 1275-1278
    CrossrefPubMedSearch in Google Scholar
  • 354 Murata K, Asano M, Matsumoto A. et al Induction of IFN-λ 3 as an additional effect of nucleotide, not nucleoside, analogues: A new potential target for HBV infection. Gut 2018; 67: 362-371
    CrossrefPubMedSearch in Google Scholar
  • 355 Heidrich B, Deterding K, Tillmann HL. et al Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat 2009; 16: 883-894
    CrossrefPubMedSearch in Google Scholar
  • 356 Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. J Hepatol 2016; 64: S102-S116
    CrossrefPubMedSearch in Google Scholar
  • 357 Amin J, Law MG, Bartlett M. et al Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938-945
    CrossrefPubMedSearch in Google Scholar
  • 358 Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347-354
    CrossrefPubMedSearch in Google Scholar
  • 359 Shi J, Zhu L, Liu S. et al A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005; 92: 607-612
    CrossrefPubMedSearch in Google Scholar
  • 360 Cho LY, Yang JJ, Ko KP. et al Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: Systematic review and meta-analysis. Int J Cancer 2011; 128: 176-184
    CrossrefPubMedSearch in Google Scholar
  • 361 Mak LY, Ka-Ho Wong D, Pollicino T. et al Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance. J Hepatol 2020; 73: 952-964
    CrossrefPubMedSearch in Google Scholar
  • 362 Wiegand SB, Jaroszewicz J, Potthoff A. et al Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect 2015; 21: 710.e1-710.e9
    CrossrefPubMedSearch in Google Scholar
  • 363 Sagnelli E, Sagnelli C, Macera M. et al An update on the treatment options for HBV/HCV coinfection. Expert Opin Pharmacother 2017; 18: 1691-1702
    PubMedSearch in Google Scholar
  • 364 Liu CJ, Chuang WL, Sheen IS. et al Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018; 154: 989-997
    CrossrefPubMedSearch in Google Scholar
  • 365 Potthoff A, Berg T, Wedemeyer H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009; 44: 1487-1490
    CrossrefPubMedSearch in Google Scholar
  • 366 Chen G, Wang C, Chen J. et al Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology 2017; 66: 13-26
    CrossrefPubMedSearch in Google Scholar
  • 367 Mücke MM, Backus LI, Mücke VT. et al Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2018; 3: 172-180
    CrossrefPubMedSearch in Google Scholar
  • 368 Omland LH, Christensen PB, Krarup H. et al Mortality among patients with cleared hepatitis C virus infection compared to the general population: A danish nationwide cohort study. PLoS One 2011; 6: e22476
    CrossrefPubMedSearch in Google Scholar
  • 369 Sarrazin C, Isakov V, Svarovskaia ES. et al Late relapse versus hepatitis c virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis 2017; 64: 44-52
    CrossrefPubMedSearch in Google Scholar
  • 370 Leumi S, Bigna JJ, Amougou MA. et al Global Burden of Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis. Clin Infect Dis 2020; 71: 2799-2806
    CrossrefPubMedSearch in Google Scholar
  • 371 Deutsch-österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. 2003
    PubMedSearch in Google Scholar
  • 372 European AIDS Clinical Society, (EACS). Treatment Guidelines 2016. 2016 Im Internet: http://www.eacsociety.org
    PubMedSearch in Google Scholar
  • 373 Gallant J, Brunetta J, Crofoot G. et al Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr 2016; 73: 294-298
    CrossrefPubMedSearch in Google Scholar
  • 374 Robert Koch-Institut. Zur Situation bei wichtigen Infektionskrankheiten in DeutschlandVirushepatitis B und D im Jahr 2014. Epidemiol Bull 2015; 29: 271-288
    PubMedSearch in Google Scholar
  • 375 Gunardi H, Iskandar MY. et al Hepatitis B virus infection in children of HBV-related chronic liver disease patients: a study of intra-familial HBV transmission. Hepatol Int 2017; 11: 96-104
    CrossrefPubMedSearch in Google Scholar
  • 376 Chen JC, Chang ML, Lin JN. et al Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area. World J Gastroenterol 2005; 11: 5289-5294
    CrossrefPubMedSearch in Google Scholar
  • 377 Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission. Expert Rev Anti Infect Ther 2004; 2: 133-145
    CrossrefPubMedSearch in Google Scholar
  • 378 Tseng YR, Wu JF, Kong MS. et al Infantile hepatitis B in immunized children: Risk for fulminant hepatitis and long-term outcomes. PLoS One 2014; 9: e111825
    CrossrefPubMedSearch in Google Scholar
  • 379 Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 2006; 78 (Suppl. 01) S43-S47
    CrossrefPubMedSearch in Google Scholar
  • 380 Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 2003; 25: 184-192
    CrossrefPubMedSearch in Google Scholar
  • 381 Lackner H, Moser A, Benesch M. et al Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy. Journal of Clinical Virology 2002; 25 (Suppl. 03) S73-S79
    CrossrefPubMedSearch in Google Scholar
  • 382 Thomas HC, Lok ASF, Locarnini SA. et al. (Hrsg) Viral Hepatitis. Wiley. Wiley-Blackwell; 2013
    PubMedSearch in Google Scholar
  • 383 Kelly D. Viral hepatitis in children. Boston, MA: Springer; 2004
    PubMedSearch in Google Scholar
  • 384 Bortolotti F, Guido M, Bartolacci S. et al Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-562
    CrossrefPubMedSearch in Google Scholar
  • 385 Popalis C, Yeung LTF, Ling SC. et al Chronic hepatitis B virus (HBV) infection in children: 25 years’ experience. J Viral Hepat 2013; 20: e20-e26
    CrossrefPubMedSearch in Google Scholar
  • 386 Wintermeyer P, Gerner P, Gehring S. et al Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children. World J Gastroenterol 2006; 12: 2235-2238
    CrossrefPubMedSearch in Google Scholar
  • 387 Chen CY, Ni YH, Chen HL. et al Lamivudine treatment in infantile fulminant hepatitis B. Pediatr Int 2010; 52: 672-674
    CrossrefPubMedSearch in Google Scholar
  • 388 Laubscher B, Gehri M, Roulet M. et al Survival of infantile fulminant hepatitis B and treatment with lamivudine. J Pediatr Gastroenterol Nutr 2005; 40: 518-520
    CrossrefPubMedSearch in Google Scholar
  • 389 Diamanti A, Sartorelli MR, Alterio A. et al Successful tenofovir treatment for fulminant hepatitis B infection in an infant. Pediatr Infect Dis J 2011; 30: 912-914
    CrossrefPubMedSearch in Google Scholar
  • 390 Hartman C, Berkowitz D, Eshach-Adiv O. et al Long-term lamivudine therapy for chronic hepatitis b infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr 2006; 43: 494-498
    CrossrefPubMedSearch in Google Scholar
  • 391 Jonas MM, Lok ASF, Mcmahon BJ. et al Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. Hepatology 2016; 63: 307-318
    CrossrefPubMedSearch in Google Scholar
  • 392 Jonas MM, Chang MH, Sokal E. et al Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology 2016; 63: 377-387
    CrossrefPubMedSearch in Google Scholar
  • 393 Jonas MM, Kelley DA, Mizerski J. et al Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-1713
    CrossrefPubMedSearch in Google Scholar
  • 394 Diem HVT, Bourgois A, Bontems P. et al Chronic hepatitis B infection: Long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr 2005; 40: 141-145
    CrossrefPubMedSearch in Google Scholar
  • 395 Hom X, Little NR, Gardner SD. et al Predictors of Virologic Response to Lamivudine Treatment in Children with Chronic Hepatitis B Infection. Pediatr Infect Dis J 2004; 23: 441-445
    CrossrefPubMedSearch in Google Scholar
  • 396 Bortolotti F, Iorio R, Pace M. et al Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715-718
    CrossrefPubMedSearch in Google Scholar
  • 397 Wirth S, Zhang H, Hardikar W. et al Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study. Hepatology 2018; 68: 1681-1694
    CrossrefPubMedSearch in Google Scholar
  • 398 Sobaniec-Lotowska ME, Lebensztejn DM. Histological outcome of chronic hepatitis B in children treated with interferon alpha. World J Gastroenterol 2005; 11: 7179-7182
    CrossrefPubMedSearch in Google Scholar
  • 399 Saltik-Temizel IN, Koçak N, Demir H. Lamivudine and high-dose interferon-α combination therapy for naive children with chronic hepatitis B infection. J Clin Gastroenterol 2005; 39: 68-70
    PubMedSearch in Google Scholar
  • 400 Defresne F, Sokal E. Chronic hepatitis B in children: Therapeutic challenges and perspectives. J Gastroenterol Hepatol 2017; 32: 368-371
    CrossrefPubMedSearch in Google Scholar
  • 401 Jonas MM, Kelly D, Pollack H. et al Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr Infect Dis J 2012; 31: 578-582
    CrossrefPubMedSearch in Google Scholar
  • 402 Jonas MM, Kelly D, Pollack H. et al Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008; 47: 1863-1871
    CrossrefPubMedSearch in Google Scholar
  • 403 Murray KF, Szenborn L, Wysocki J. et al Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56: 2018-2026
    CrossrefPubMedSearch in Google Scholar
  • 404 Carey I, D’Antiga L, Bansal S. et al Immune and Viral Profile from Tolerance to Hepatitis B Surface Antigen Clearance: a Longitudinal Study of Vertically Hepatitis B Virus-Infected Children on Combined Therapy. J Virol 2011; 85: 2416-2428
    CrossrefPubMedSearch in Google Scholar
  • 405 Poddar U, Yachha SK, Agarwal J. et al Cure for immune-tolerant hepatitis B in children: Is it an achievable target with sequential combo therapy with lamivudine and interferon?. J Viral Hepat 2013; 20: 311-316
    CrossrefPubMedSearch in Google Scholar
  • 406 Zhu S, Zhang H, Dong Y. et al Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J Hepatol 2018; 68: 1123-1128
    CrossrefPubMedSearch in Google Scholar
  • 407 Rosenthal P, Ling SC, Belle SH. et al Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen–Positive Immune Tolerant Chronic Hepatitis B Virus Infection. Hepatology 2019; 69: 2326-2337
    CrossrefPubMedSearch in Google Scholar
  • 408 Robert Koch-Institut. Impfstatus der Kinder und Jugendlichen in Deutschland, STIKO: Influenzaimpfungen in der COVID-19-Pandemie. Epidemiol Bull 2020; 32/33: 12
    PubMedSearch in Google Scholar
  • 409 Lee C, Gong Y, Brok J. et al Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: Systematic review and meta-analysis. Br Med J 2006; 332: 328-332
    CrossrefPubMedSearch in Google Scholar